HC Deb 11 September 2003 vol 410 cc420-1W
John Barrett

To ask the Minister of State, Department for International Development what plans there are to expand the use of the RTSS/ASO2A malaria vaccine following its trial in Mozambique. [127935]

Hilary Benn

The RTSS/ASO2A vaccine (a GlaxoSmithKline (GSK) Biologicals' product) is a new product for malaria which has yet to undergo the full approval process.

An international partnership involving GSK, Mozambique's Ministry of Health (MOH), and Centro de Investigacio em Saude de Manhica (CISM), the Hospital Clinic of the University of Barcelona, and the Program for Appropriate Technology in Health (PATH)'s Malaria Vaccine Initiative (MVI) has now conducted phase 2 paediatric clinical trials.

The UK Government welcome the apparent success of the vaccine to date, but will wait to see the final outcome of the trials before planning any expansion of its use.

Back to
Forward to